Resultados da pesquisa - David K. Chang
- A mostrar 1 - 20 resultados de 55
- Go to Next Page
-
1
-
2
-
3
-
4
BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer Por Michael J. Pishvaian, Andrew V. Biankin, Peter J. Bailey, David K. Chang, Daniel A. Laheru, Christopher L. Wolfgang, Jonathan R. Brody
Publicado em 2017Artigo -
5
Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine Por Raffaella Casolino, Chiara Braconi, Giuseppe Malleo, Salvatore Paiella, Claudio Bassi, Michèle Milella, Stephan Dreyer, Fieke E. M. Froeling, David K. Chang, Andrew V. Biankin, Talia Golan
Publicado em 2020Revisão -
6
Aberrant methylmalonylation underlies methylmalonic acidemia and is attenuated by an engineered sirtuin Por PamelaSara E. Head, Sangho Myung, Yong Chen, Jessica L. Schneller, Cindy Wang, Nicholas R. Duncan, Pauline R. Hoffman, David K. Chang, Abigael Gebremariam, Marjan Guček, Irini Manoli, Charles P. Venditti
Publicado em 2022Artigo -
7
Recruitment and Activation of Pancreatic Stellate Cells from the Bone Marrow in Pancreatic Cancer: A Model of Tumor-Host Interaction Por Christopher J. Scarlett, Emily K. Colvin, Mark Pinese, David K. Chang, Adrienne Morey, Elizabeth A. Musgrove, Marina Pajic, Minoti V. Apte, Susan M. Henshall, Robert L. Sutherland, James G. Kench, Andrew V. Biankin
Publicado em 2011Artigo -
8
Jorunnamycin A induces apoptosis in pancreatic ductal adenocarcinoma cells, spheroids, and patient-derived organoids by modulating KRAS-mediated survival pathways Por Hnin Ei Ei Khine, Utid Suriya, Thanyada Rungrotmongkol, Supakarn Chamni, Yanxi Lu, Alan Bénard, Bin Lan, Debabrata Mukhopadhyay, David K. Chang, Andrew V. Biankin, Regine Schneider‐Stock, Robert Grützmann, Rungroch Sungthong, Christian Pilarsky, Chatchai Chaotham
Publicado em 2025Artigo -
9
Neuropilin-2 Promotes Extravasation and Metastasis by Interacting with Endothelial α5 Integrin Por Ying Cao, Luke H. Hoeppner, Steven Bach, E Guangqi, Yan Guo, Enfeng Wang, Jianmin Wu, Mark J. Cowley, David K. Chang, Nicola Waddell, Sean M. Grimmond, Andrew V. Biankin, Roger J. Daly, Xiao Hui Zhang, Debabrata Mukhopadhyay
Publicado em 2013Artigo -
10
Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma Por Peter J. Bailey, David K. Chang, Marie‐Andrée Forget, F. Anthony San Lucas, Hector A. Alvarez, Cara Haymaker, Chandrani Chattopadhyay, Sun-Hee Kim, Sühendan Ekmekçioğlu, Elizabeth A. Grimm, Andrew V. Biankin, Patrick Hwu, Anirban Maitra, Jason Roszik
Publicado em 2016Artigo -
11
Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling Por Stephan Dreyer, Nigel B. Jamieson, Lisa Evers, Fraser R. Duthie, Susie Cooke, John L. Marshall, Dario Beraldi, Stephen R Knight, Rosanna Upstill‐Goddard, Euan J. Dickson, C. Ross Carter, Colin J. McKay, Andrew V. Biankin, David K. Chang
Publicado em 2019Artigo -
12
Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma Por Michael E. Feigin, Tyler H. Garvin, Peter J. Bailey, Nicola Waddell, David K. Chang, David R. Kelley, Shimin Shuai, Steven Gallinger, John D. McPherson, Sean M. Grimmond, Ekta Khurana, Lincoln Stein, Andrew V. Biankin, Michael C. Schatz, David A. Tuveson
Publicado em 2017Artigo -
13
Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis Por Raffaella Casolino, Salvatore Paiella, Danila Azzolina, Philip Beer, Vincenzo Corbo, Giulia Lorenzoni, Darío Gregori, Talia Golan, Chiara Braconi, Fieke E. M. Froeling, Michèle Milella, Aldo Scarpa, Antonio Pea, Giuseppe Malleo, Roberto Salvia, Claudio Bassi, David K. Chang, Andrew V. Biankin
Publicado em 2021Revisão -
14
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer Por Rowan Miller, Alexandra Léary, Clare L. Scott, Violeta Serra, Christopher J. Lord, David D.L. Bowtell, David K. Chang, Dale W. Garsed, Jos Jonkers, Jonathan A. Ledermann, Serena Nik‐Zainal, Isabelle Ray‐Coquard, Sohrab P. Shah, Xavier Matías‐Guiu, Elizabeth M. Swisher, Lucy Yates
Publicado em 2020Revisão -
15
Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects Por Glenn M. Marshall, Samuele Gherardi, Ning Xu, Zillan Neiron, Toby N. Trahair, Christopher J. Scarlett, David K. Chang, Peiyuan Liu, Kacper Jankowski, Nunzio Iraci, Michelle Haber, Murray D. Norris, Joanna Keating, Eric Sekyere, Georg von Jonquières, Fabio Stossi, Benita S. Katzenellenbogen, Andrew V. Biankin, Giovanni Perini, Tao Liu
Publicado em 2010Artigo -
16
Adjuvant chemotherapy in elderly patients with pancreatic cancer Por Adnan Nagrial, David K. Chang, Nam Q. Nguyen, Amber L. Johns, Lorraine A. Chantrill, Jeremy L. Humphris, Venessa Chin, Jaswinder S. Samra, Anthony J. Gill, Marina Pajic, Mark Pinese, Emily K. Colvin, Christopher J. Scarlett, Angela Chou, James G. Kench, R. L. Sutherland, Lisa G. Horvath, Andrew V. Biankin
Publicado em 2013Artigo -
17
PDX1 dynamically regulates pancreatic ductal adenocarcinoma initiation and maintenance Por Nilotpal Roy, Kenneth K. Takeuchi, Jeanine Ruggeri, Peter J. Bailey, David K. Chang, Joey H. Li, Laura Leonhardt, Sapna Puri, Megan T. Hoffman, Shan Gao, Christopher J. Halbrook, Yan Song, Mats Ljungman, Shivani Malik, Christopher V.E. Wright, David W. Dawson, Andrew V. Biankin, Matthias Hebrok, Howard C. Crawford
Publicado em 2016Artigo -
18
Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2 Por Hemant M. Kocher, Charlotte Ackerman, Garima Priyadarshini, Cheryl Lawrence, Nishtha Kotriwala, Ramona Georgescu, Rhiannon Roberts, Christine S. Hughes, Ahmet Imrali, Claude Chelala, Judith Dixon-Hughes, David K. Chang, Peter Sasieni, Pippa Corrie, Mairéad G. McNamara, Debashis Sarker, Fieke E. M. Froeling, Alan Christie, Roopinder Gillmore, Khurum Khan, David Propper
Publicado em 2025Artigo -
19
The prognostic and predictive value of serum CA19.9 in pancreatic cancer Por Jeremy L. Humphris, David K. Chang, Amber L. Johns, Christopher J. Scarlett, Marina Pajic, Marc D. Jones, Emily K. Colvin, Adnan Nagrial, Venessa Chin, Lorraine A. Chantrill, Jaswinder S. Samra, Anthony J. Gill, James G. Kench, Neil D. Merrett, Anibh M. Das, Elizabeth A. Musgrove, R. L. Sutherland, Andrew V. Biankin
Publicado em 2012Artigo -
20
<i>Sleeping Beauty</i> mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma Por Karen M. Mann, Jerrold M. Ward, Christopher Chin Kuan Yew, Anne Kovochich, David W. Dawson, Michael A. Black, Benjamin T. Brett, Todd E. Sheetz, Adam J. Dupuy, David K. Chang, Andrew V. Biankin, Nicola Waddell, Karin S. Kassahn, Sean M. Grimmond, Alistair G. Rust, David J. Adams, Nancy A. Jenkins, Neal G. Copeland
Publicado em 2012Artigo
Ferramentas de pesquisa:
Assuntos relacionados
Biology
Cancer
Medicine
Pancreatic cancer
Internal medicine
Cancer research
Gene
Genetics
Oncology
Bioinformatics
Mutation
Adenocarcinoma
Biochemistry
Pathology
Carcinogenesis
Chemistry
Pancreatic ductal adenocarcinoma
Computational biology
Computer science
DNA
Germline mutation
KRAS
Pancreas
Chemotherapy
Colorectal cancer
Surgery
Clinical trial
Cohort
Disease
Gastroenterology